PDCD1 and non-small cell lung carcinoma: As another anti-PD-1 mAb, pembrolizumab received FDA approval in October 2014 and can be used for treating epidermal growth factor receptor (EGFR) mutation-negative and ALK rearrangement-negative NSCLC that has progressed on or after platinum-based chemotherapy.